Lv41
410 积分 2024-07-06 加入
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial
7小时前
已完结
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
18小时前
已完结
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial
19小时前
已完结
Emerging Therapeutic Synergies: Combining PD-1 Inhibitors With Poly-ADP-Ribose Polymerase (PARP) Inhibitors in the Treatment of Gynecologic Cancers
1个月前
已完结
Upregulation of CXCL1 and LY9 contributes to BRCAness in ovarian cancer and mediates response to PARPi and immune checkpoint blockade
1个月前
已完结
Identification of CXCL13 as a Promising Biomarker for Immune Checkpoint Blockade Therapy and PARP Inhibitor Therapy in Ovarian Cancer
1个月前
已完结
Dissecting the Distinct Tumor Microenvironments of HRD and HRP Ovarian Cancer: Implications for Targeted Therapies to Overcome PARPi Resistance in HRD Tumors and Refractoriness in HRP Tumors
1个月前
已完结
Contraception as chemoprevention of ovarian cancer in BRCA1 and BRCA2 women
7个月前
已完结
Oral contraceptives and risk of ovarian and breast cancers inBRCAmutation carriers: a meta-analysis
7个月前
已完结
Oral contraceptives and risk of ovarian and breast cancers inBRCAmutation carriers: a meta-analysis
7个月前
已关闭
皖公网安备34019202002308
